Tmunity adds $35M to series A round
T cell immunotherapy company Tmunity Therapeutics Inc. (Philadelphia, Pa.) raised an additional $35 million for its series A round from Kleiner Perkins and affiliates, bringing the round's total to $135 million. In January, the company raised $100 million from Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences Inc. (NASDAQ:GILD), Be The Match BioTherapies, Penn Medicine and Lilly Asia Ventures (see BioCentury, Jan. 26).
Tmunity was founded by Carl June and other faculty and researchers at the University of Pennsylvania. It has an exclusive license to platforms from the university to develop and commercialize engineered T cell immunotherapies for cancer, infectious diseases and autoimmune diseases, including T cell receptors (TCRs), regulatory T cells and CAR T cells (see BioCentury, Jan. 26)...